fromFortune
1 week agoI'm the CEO of GoodRx. A new era of access demands smarter design for direct-to-consumer drug pricing
The national conversation around prescription drug pricing is back in full force. From the recent Most Favored Nation (MFN) executive order to President Trump's letter urging pharmaceutical companies to offer direct-to-consumer (DTC) pricing for brand medications, it's clear we're at a pivotal moment for American healthcare. It's a moment that demands more than just rhetoric; it demands innovation, pragmatism, and above all, deep collaboration across the industry.
Medicine